Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 6:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heavy Menstrual Bleeding Clear all
Completed Not applicable Interventional Results available

Sonography Guided Transcervical Ablation of Uterine Fibroids

NCT02228174
View directory record Official record
Conditions
Menorrhagia
Interventions
Intrauterine Ultrasound-Guided Radiofreq. Ablation System
Device
Lead sponsor
Gynesonics
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Denver, Colorado • Newark, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 9, 2026, 6:13 AM EDT
Not listed Not applicable Interventional

Stopping Heavy Periods Project

NCT02002260
View directory record Official record
Conditions
Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Interventions
Levonorgestrel intrauterine system, Combined oral contraceptives
Device · Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Sep 9, 2026, 6:13 AM EDT
Not yet recruiting Phase 4 Interventional

Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy

NCT07664956
View directory record Official record
Conditions
Minimally Invasive Surgical Procedures, Abnormal Uterine Bleeding, Unspecified, Adenomyosis of Uterus, Fibroid Uterus, Chronic Pelvic Pain, Endometriosis, Menorrhagia, Endometritis, Adnexal Diseases
Interventions
Cyclobenzaprine
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 9, 2026, 6:13 AM EDT
Terminated No phase listed Observational

Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding

NCT05685199
View directory record Official record
Conditions
Hypermobile Ehlers-Danlos Syndrome, Heavy Menstrual Bleeding, Hypermobility Syndrome (Disorder)
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 40 Years · Female only
Enrollment
15 participants
Timeline
2024 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 9, 2026, 6:13 AM EDT
Withdrawn No phase listed Observational

A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

NCT06058728
View directory record Official record
Conditions
Uterine Fibroids (UF)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 9, 2026, 6:13 AM EDT
Completed Not applicable Interventional Results available

Registry Study of Genesys HTA for Treatment of Menorrhagia

NCT01197547
View directory record Official record
Conditions
Menorrhagia
Interventions
Genesys HTA
Device
Lead sponsor
Minerva Surgical, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
San Diego, California • Newark, Delaware • Athens, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 9, 2026, 6:13 AM EDT
Completed Not applicable Interventional

Treatment and Management of Women With Bleeding Disorders

NCT00111215
View directory record Official record
Conditions
Menorrhagia, Blood Coagulation Disorders, Blood Platelet Disorders, Von Willebrand Disease, Hematologic Disease
Interventions
Tranexamic Acid, Desmopressin Acetate
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Atlanta, Georgia • East Lansing, Michigan • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2007 · Synced Sep 9, 2026, 6:13 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

HMB- Data Collection Methods

NCT02001324
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Web-based data collection, Paper-based data collection
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 9, 2026, 6:13 AM EDT
Completed Not applicable Interventional

Post Market TRUST - U.S.A. Study

NCT02163525
View directory record Official record
Conditions
Symptomatic Uterine Fibroids
Interventions
Global Fibroid Ablation (GFA), Abdominal or Laparoscopic Myomectomy, Uterine Artery Embolization (UAE)
Procedure
Lead sponsor
Acessa Health, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
9
States / cities
Santa Monica, California • Walnut Creek, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 9, 2026, 6:13 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 9, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding

NCT00395993
View directory record Official record
Conditions
Anemia
Interventions
Ferric Carboxymaltose (FCM), Ferrous Sulfate tablets
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 9, 2026, 6:13 AM EDT
Completed Not applicable Interventional Results available

A CLinical Study to Evaluate the Safety And Effectiveness of the CeRene DevIce to Treat HeavY Menstrual Bleeding

NCT02842736
View directory record Official record
Conditions
Menorrhagia
Interventions
Cerene(R) Cryotherapy Device
Device
Lead sponsor
Channel Medsystems
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Arlington Heights, Illinois • Naperville, Illinois • Fort Wayne, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 9, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

NCT03317795
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
Interventions
Levonorgestrel IUS, Tranexamic Acid
Drug
Lead sponsor
Shannon K. Laughlin-Tommaso
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 9, 2026, 6:13 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

NCT01391052
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Hypermenorrhea
Interventions
Norethindrone acetate pretreatment, No pretreatment
Drug · Other
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2011 · Synced Sep 9, 2026, 6:13 AM EDT
Completed No phase listed Observational Results available

A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test

NCT01740687
View directory record Official record
Conditions
Contraception, Menorrhagia
Interventions
ESS305 (Essure, BAY1454032), NovaSure
Device · Procedure
Lead sponsor
Bayer
Industry
Eligibility
21 Years to 50 Years · Female only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
17
States / cities
Aurora, Colorado • Ocala, Florida • Decatur, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 9, 2026, 6:13 AM EDT
Not listed Not applicable Interventional

Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding

NCT01659008
View directory record Official record
Conditions
Menstrual Cycle and Uterine Bleeding Disorders
Interventions
Estradiol, Lysteda
Drug
Lead sponsor
Kay I Waud MD PhD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 9, 2026, 6:13 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution

NCT01581905
View directory record Official record
Conditions
Menorrhagia, Dysfunctional Uterine Bleeding, Leiomyoma, Pelvic Pain, Endometriosis
Interventions
Conventional Laparoscopic Hysterectomy (LH), Robot Assisted Hysterectomy
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 9, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of XP12B in Women With Menorrhagia

NCT00386308
View directory record Official record
Conditions
Menorrhagia, Heavy Menstrual Bleeding
Interventions
Tranexamic acid tablets, Placebo tablets
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Tucson, Arizona • Little Rock, Arkansas • Carmichael, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Sep 9, 2026, 6:13 AM EDT
Withdrawn Phase 4 Interventional

Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis

NCT03325868
View directory record Official record
Conditions
Adenomyosis, Heavy Uterine Bleeding, Dysmenorrhea
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 51 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 9, 2026, 6:13 AM EDT
Completed Not applicable Interventional

Hysteroscopic Assessment of Fallopian Tubal Patency

NCT02005263
View directory record Official record
Conditions
Infertility, Menorrhagia
Interventions
Salpingography
Procedure
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 9, 2026, 6:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Truclear on Patient Quality of Life

NCT02934789
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Hysteroscopic myomectomy with Truclear, Medical therapy
Procedure · Drug
Lead sponsor
All For Women Healthcare, Illinois
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 9, 2026, 6:13 AM EDT
Completed Not applicable Interventional

Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

NCT06634719
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Juveena Hydrogel System
Device
Lead sponsor
Rejoni Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Little Rock, Arkansas • West Orange, New Jersey • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 9, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03049735
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
76
States / cities
Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 9, 2026, 6:13 AM EDT
Terminated No phase listed Observational

A Retrospective Review Of Outcomes Following Laparoscopic Myomectomy

NCT00672750
View directory record Official record
Conditions
Laparoscopic Myomectomy
Interventions
Not listed
Lead sponsor
The Advanced Gynecologic Surgery Institute
Other
Eligibility
16 Years to 70 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 9, 2026, 6:13 AM EDT